香港又一耐“达菲”流感 变异毒株大面积扩散？

　　

生物通报道，首例对达菲耐药的新闻报道还未曾离我们远去，最近相继有日本和香港爆出第二例，第三例的流感耐药事件，专家们提高了流感对达菲耐药的警惕，专家们担心耐药流感毒株已经传播开来！

 

第一例6月29号  丹麦

最初爆出的耐药毒株出现在丹麦，6月29日，罗氏公司证实丹麦一名流感患者对达菲产生耐药。患者在接受达菲治疗的过程中发现毒株已经产生耐药性，所幸患者并没有机会将耐药毒株传播出去。

 

第二例 7月2号  日本

据报道，第二例流感耐药发生在7月2日的日本境内，情况与第一例相似，患者在接受治疗的过程中产生耐药。

 

第三例 7月3号  香港

第三例流感耐药发生在7月3日的香港，患者是一名16岁的青年女性，6月11号搭乘从旧金山-香港的航班返回香港，发病期间只出现轻微的症状，并未接受达菲的治疗。这表明，患者所感染的毒株已经在加州传播开来，并且已经发生耐药变异。

 

澳大利亚墨尔本联邦科学与工业研究所病毒学家Jennifer Mckimm-Breschkin表示，现在令人担忧的是，新的流感病毒不仅具有适应人群的本领，还具有良好的耐药突变性和传播性。

 

据悉，除开达菲，一种与达菲类似的化学药物zanamivir对新流感有抵抗力！

 

生物通点评：频频出现的达菲耐药情况给人类敲响警钟，流感病毒的变异速递远比我们想象的要快！储备的达菲是否因耐药毒株的出现而失效，面对耐药的毒株，面对进一步扩散的流感疫情，我们该怎么办？科研单位是否该相机而动，尽早开发其他抗流感药物？

（生物通 小茜）

 

Roche更多流感相关详细资料

 

 

Hong Kong Case Suggests Resistant Swine Flu May Be Spreading

A third case of oseltamivir-resistant swine flu, announced today in Hong Kong, has flu experts worried that resistance to the drug is spreading. Unlike the previous two cases, the Hong Kong patient hadn’t taken oseltamivir herself, which suggests she picked up a resistant strain from someone else.

 

When Denmark reported its first known resistant case of 2009 A(H1N1) swine flu on Tuesday, scientists weren’t alarmed yet, because the virus most likely developed resistance while the patient was being treated and there was no evidence that she had infected anybody else. A second case, reported yesterday from Japan, also appears to have arisen while the patient took the drug. In the past, such drug-induced mutant viruses have often not spread very well.

 

The Hong Kong case is different: The patient, a 16-year-old girl intercepted at Hong Kong International Airport on 11 June after flying in from San Francisco, had only mild symptoms and never took oseltamivir, Hong Kong health authorities reported today. That suggests this strain is already circulating in California and may not be hampered by the resistance mutation.

 

“It’s very disturbing that, fresh into the human population, this [virus] appears now to be able to retain fitness despite having the mutation and to be able to spread,” virologist Jennifer McKimm-Breschkin of the Commonwealth Science and Industrial Research Organisation in Melbourne, Australia, told Bloomberg today.

 

Tests showed that the resistant virus is still susceptible to zanamivir, a chemical cousin of oseltamivir that some countries have added to their pandemic stockpiles.